載入中
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
前收盤價
US$21.11
+US$0.66 · +3.23%
盤中時間採用ET。市場資料可能有所延遲。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日內區間
目前US$21.11
52週區間
目前US$21.11
盤中時間採用ET。市場資料可能有所延遲。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日內區間
目前US$21.11
52週區間
目前US$21.11
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 33.5萬 USD | — | — | — | — |
| 毛利 | −33.5萬 USD | — | — | — | — |
| 研究與開發 | 3873.2萬 USD | 3501.6萬 USD | 2982.1萬 USD | 2048.4萬 USD | 855.3萬 USD |
| 銷售、一般及管理費用 | 2160.9萬 USD | 1500.2萬 USD | 1112.1萬 USD | 1005.6萬 USD | 654.2萬 USD |
| 營業費用 | 6034.1萬 USD | 5031.2萬 USD | 4122.2萬 USD | 3055.4萬 USD | 1510萬 USD |
| 利息收入 | 262.5萬 USD | 262.8萬 USD | 189萬 USD | 85.8萬 USD | 9 USD |
| 利息支出 | 46.3萬 USD | 71.7萬 USD | 72.3萬 USD | — | 9000 USD |
| 折舊和攤銷 | 33.5萬 USD | 31.5萬 USD | 31.5萬 USD | 4.7萬 USD | 1.9萬 USD |
| 營業利益 | −6067.6萬 USD | −5031.2萬 USD | −4122.2萬 USD | −3055.4萬 USD | −1510萬 USD |
| 淨利 | −4825.8萬 USD | −3896.1萬 USD | −3558.7萬 USD | −2245.6萬 USD | −920.2萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB806.7萬0.08%108.2億 USD0.44%US$206.49+3.00%
AdvisorShares Psychedelics ETFPSIL194.29萬4.15%4685.29萬 USD1.84%US$21.765+3.69%
iShares MSCI Ireland ETFEIRL107.9萬1.44%7459.97萬 USD0.50%US$78.50-1.14%
Virtus Biotech Clinical Trials ETFBBC30.73萬0.75%4099.65萬 USD0.65%US$44.1456+2.08%
Invesco Nasdaq Biotechnology ETFIBBQ10.8萬0.10%1.12億 USD0.19%US$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB5.57萬0.06%9320.36萬 USD1.19%US$110.98+5.68%
First Trust IPOX Europe Equity Opportunities ETFFPXE1.1萬0.23%472.63萬 USD0.70%US$31.665-2.15%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
